Lung cancer screening trial using tumor and blood test results
Part of Cancer, Lungs & breathing clinical trials.
This trial helps sort people with previously treated lung cancer into the best next treatment options by using new tumor tissue (and sometimes blood) test results. It may help you get matched to therapies based on features like PD-L1 and other biomarkers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer (any subtype) proven by a biopsy or fine-needle sample
- Your cancer is stage IV or has come back (recurrent)
- You must be able to provide enough tumor tissue for testing (at least 20% tumor cells and enough tumor volume)
- You must share your tumor sample with Foundation Medicine for biomarker tests, and agree to keep leftover tissue for future research
- You must be 18 or older and able to do daily activities fairly normally (performance status 0–1)
- You cannot have certain common gene changes (EGFR, ALK, ROS1, BRAF) unless you already tried the standard targeted treatments for them
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how tumor and blood biomarker results can guide treatment for people with non-small cell lung cancer (NSCLC). Depending on the cancer stage, it may follow standard-of-care treatment plans around surgery or first-line immunotherapy.
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
This study uses a special blood test to track minimal residual disease (tiny amounts of cancer that may remain) in people with stage IIIB-C non-small cell lung cancer after they receive initial chemotherapy plus immunotherapy. It may help doctors understand whether this blood test can guide further care and improve outcomes.
This trial tests tumor tissue and a blood sample to help doctors pick the most personalized treatment for people with suspected lung cancer. It may help ensure you get therapy matched to your specific tumor characteristics, especially when the cancer might be surgically removed.
This study uses a blood test called ctDNA to look for leftover lung cancer after surgery. Based on that result, the trial will help decide which treatment approach is best for you and may catch cancer returning earlier.
This trial uses a special blood test to look for tiny cancer DNA to estimate your risk of the cancer getting worse after first immunotherapy. It aims to help doctors monitor progression earlier and more accurately in advanced lung cancer.
Hear when a new Previously Treated Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.